Search

Your search keyword '"Parihar, Ashwin Singh"' showing total 290 results
Start Over Author "Parihar, Ashwin Singh"
290 results on '"Parihar, Ashwin Singh"'

6. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects

Author

Park, Sonya, Parihar, Ashwin Singh, Bodei, Lisa, Hope, Thomas A, Mallak, Nadine, Millo, Corina, Prasad, Kalpna, Wilson, Don, Zukotynski, Katherine, and Mittra, Erik

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Biomedical Imaging, Cancer, Neurosciences, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Neuroendocrine Tumors, Positron-Emission Tomography, Precision Medicine, Receptors, Somatostatin, somatostatin, SSTR, peptide receptor radionuclide ther-apy, neuroendocrine neoplasms, Ga-68-DOTATATE, Ga-68-DOTANOC, 68Ga-DOTANOC, 68Ga-DOTATATE, peptide receptor radionuclide therapy, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based γ-scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy-based Krenning score for PRRT eligibility. Also, to date, the role of SSTR PET in response assessment and predicting outcome remains under evaluation. In this comprehensive review article, we discuss the current role of SSTR PET in all aspects of neuroendocrine neoplasms, including its relation to conventional imaging, selection of patients for PRRT, and the current understanding of SSTR PET-based response assessment. We also provide a standardized reporting template for SSTR PET with a brief discussion.

Published
2021

7. Radionuclide Therapy of Lymphomas

Author

Parihar, Ashwin Singh, Jacene, Heather A., Tirumani, Sree Harsha, Wahl, Richard L., Volterrani, Duccio, editor, Erba, Paola A., editor, Strauss, H. William, editor, Mariani, Giuliano, editor, and Larson, Steven M., editor

Published
2022
Full Text
View/download PDF

49. Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy

Author

Parihar, Ashwin Singh, Chandekar, Kunal Ramesh, Singh, Harpreet, Sood, Ashwani, and Mittal, Bhagwant Rai

Subjects
pet/ct, lcsh:Medical physics. Medical radiology. Nuclear medicine, lcsh:Biology (General), lcsh:R895-920, prostate specific membrane antigen, Case Report, cns, urologic and male genital diseases, prostate cancer, lcsh:QH301-705.5, ocular
Abstract

We present a case of metastatic prostate cancer with rare metastases involving the brain and orbit, in addition to liver, skeletal and nodal metastases. The patient had undergone prior hormonal therapy and chemotherapy and had disease progression despite 2 cycles of (177)Lu-Prostate specific membrane antigen ((177)Lu-PSMA) based radioligand therapy. He had a partial response after 2 cycles of (225)Ac-PSMA based targeted alpha therapy, as demonstrated on the (68)Ga-PSMA PET/CT study. However, the patient had disease progression at the end of 4 cycles of (225)Ac-PSMA therapy, evident by rising prostate specific antigen levels and imaging findings. The end of treatment (68)Ga-PSMA PET/CT showed additional sites of metastases in the orbit and brain apart from overall disease progression. These are rare sites of distant spread in prostate cancer and require urgent evaluation and local treatment to prevent potential complications. The importance of detection of metastatic sites in closed cavities is because of the requirement for urgent intervention to avoid compression related complications.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results